Entrectinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 63 min read
Entrectinib - Uses, Dosage, Side Effects, Interaction
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B, and C, C-ros 1 (ROS1) and anaplastic kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1, and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1, and ALK are overexpressed in a variety of cancer cell types.

Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations. Serum aminotransferase elevations are common during therapy but the clinically apparent injury is rare, although it has been reported.

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[rx] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumors.[rx] Entrectinib’s approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefits over similar ALK inhibitors such as alectinib, ceritinib, and lorlatinib due to a wider range of targets.[rx]

Mechanism of Action

Entrectinib is a tyrosine kinase inhibitor that acts on several receptors. It functions as an ATP competitor to inhibit tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC, as well as proto-oncogene tyrosine-protein kinase ROS1 and anaplastic lymphoma kinase (ALK). TRK receptors produce cell proliferation via downstream signaling through the mitogen-activated protein kinase, phosphoinositide 3-kinase, and phospholipase C-γ. ALK produces similar signaling with the addition of downstream JAK/STAT activation. Inhibition of these pathways suppresses cancer cell proliferation and shifts the balance in favor of apoptosis resulting in the shrinking of tumor volume.

Indications

  • Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment of NTRK gene fusion-positive solid tumors which have metastasized or for which surgical resection is likely to result in morbidity and for which has progressed on previous therapies or for which no comparable alternative therapies are available.
  • Rozlytrek as monotherapy is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor who have no satisfactory treatment options.
  • Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1-positive, advanced nonsmall cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.
  • Entrectinib is an oral selective inhibitor of the neurotrophic T receptor kinase (NTRK) and ROS1 that is used to treat solid tumors with NTRK gene fusion and non-small cell lung cancer with ROS1 mutations.
  • Metastatic Non-Small Cell Lung Cancer
  • Solid Metastatic Tumor
  • Solid Tumors

In the US, entrectinib is indicated to treat patients whose cancers are ROS1-positive (have a specific feature ()).[rx] It is to be used in those with solid tumors that:[rx]

  • are caused by certain abnormal neurotrophic tyrosine receptor kinase (NTRK) genes, and
  • have spread or if surgery to remove their cancer is likely to cause severe complications, and
  • there is no acceptable treatment, or the cancer grew or spreads on other treatment

Entrectinib is not approved for use in those less than twelve years of age.

In the European Union, entrectinib as monotherapy is indicated for the treatment of adults and adolescents twelve years of age and older with solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,[rx]

  • who have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and[rx]
  • who have not received a prior NTRK inhibitor[rx]
  • who have no satisfactory treatment options?[rx]

It is also indicated for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.[rx]

Use in Cancer

Entrectinib is approved to treat:

  • Non-small cell lung cancer that is ROS1 positive. It is used in adults whose cancer has metastasized (spread to other parts of the body).
  • Solid tumors that have an NTRK gene fusion without a  mutation in certain TRK proteins. It is used in adults and in children aged 12 years or older whose cancer has metastasized or cannot be removed by surgery and has gotten worse after other treatments or cannot be treated with other therapies.¹

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that entrectinib provides a benefit in these patients.

Entrectinib is also being studied in the treatment of other types of cancer.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • abnormal EKG with QT changes from birth
  • liver problems
  • high amount of uric acid in the blood
  • pregnancy
  • a patient who is producing milk and breastfeeding

Strengths: 100 mg; 200 mg

Non-Small Cell Lung Cancer

  • 600 mg orally once a day until or unacceptable toxicity
  • For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Solid Tumors

  • 600 mg orally once a day until disease or unacceptable toxicity
  • For adult patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy.

Pediatric Dose for Solid Tumors

12 years and older:

  • Body surface area (BSA) greater than 1.5 m2: 600 mg orally once a day
  • BSA 1.11 to 1.5 m2: 500 mg orally once a day
  • BSA 0.91 to 1.1 m2: 400 mg orally once a day

Dose Adjustments

  • or renal impairment (CrCl 30 to less than 90 mL/min: No adjustment recommended.
  • Severe renal impairment (CrCl greater than 30 mL/min): Data not available

Liver Dose Adjustments

  • Grade 3 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or ; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; resume at a reduced dose for Grade 3 events that resolve within 4 weeks.
  • Grade 4 hepatic impairment: Withhold therapy until recovery to less than or equal to Grade 1 or baseline; resume at a reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.
  • ALT or AST greater than 3 times the upper limit of normal (ULN) with concurrent total greater than 1.5 x ULN (in the absence of cholestasis or hemolysis): Permanently discontinue therapy.

Dose Adjustments

DOSE REDUCTIONS FOR ADVERSE REACTIONS:
FIRST DOSE REDUCTION:

  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 400 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 300 mg orally once daily

SECOND DOSE REDUCTION (if the patient cannot tolerate the second dose reduction permanently discontinue therapy):

  • Adults and pediatric patients 12 years and older with BSA greater than 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 1.11 to 1.50 m2: 200 mg orally once daily
  • Pediatric patients 12 years and older with BSA of 0.91 to 1.1 m2: 200 mg orally once daily

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:
:

  • Grade 2 or 3: Withhold therapy until recovered to less than or equal to Grade 1; resume at a reduced dose.
  • Grade 4: Permanently discontinue therapy.

CENTRAL NERVOUS SYSTEM EFFECTS:

  • Intolerable Grade 2: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose.
  • Grade 3: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose if resolution occurs within 4 weeks; permanently discontinue if the adverse reaction does not resolve within 4 weeks; resume at a reduced dose for recurrent Grade 3 events that resolve within 4 weeks.
  • Grade 4: Withhold therapy until recovered to less than or equal to Grade 1 or baseline; resume at the same dose or reduced dose if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue therapy for recurrent Grade 4 events.

HYPERURICEMIA:

  • QTc greater than 500 ms: Withhold therapy until QTc interval recovers to baseline; resume at the same dose if factors that cause QT prolongation are identified and corrected; resume at a reduced dose if other factors that cause QT prolongation are not identified.
  • Torsade de Pointes; polymorphic ; signs/symptoms of serious : Permanently discontinue therapy.

VISION DISORDERS:

  • Grade 2 or higher: Withhold therapy until improvement or stabilization; resume at the same dose or reduced dose as appropriate.

OR :

  • Grade 3 or 4: Withhold therapy until adverse reaction resolves or improves to recovery or improvement to Grade 1 or baseline; resume at the same or reduced dose, if resolution occurs within 4 weeks; permanently discontinue if an adverse reaction does not resolve within 4 weeks; permanently discontinue for recurrent Grade 4 events.

DOSAGE MODIFICATIONS FOR DRUG INTERACTIONS: MODERATE AND STRONG CYP450 3A INHIBITORS:
Adults and pediatric patients 12 years and older with BSA Greater than 1.5 m2: Avoid coadministration of this drug with moderate or strong CYP450 3A inhibitors; if coadministration cannot be avoided, reduce the dose of this drug as follows:

  • Moderate CYP450 3A Inhibitors: 200 mg orally once daily
  • Strong CYP450 3A Inhibitors: 100 mg orally once daily

After discontinuation of a strong or moderate CYP450 3A inhibitor for 3 to 5 elimination half-lives, resume the dose that was taken prior to initiating the CYP450 3A inhibitor.

Administration advice:

  • This drug may be taken with or without food.
  • Swallow capsules whole do not open, crush, chew, or dissolve the contents of the capsule.
  • If a dose is missed, take it as soon as it is remembered unless the next dose is due within 12 hours.
  • If a patient vomits immediately after taking a dose, instruct them to repeat that dose.

Side Effects

The Most Common

  • tiredness
  • taste changes
  • cough, fever, or other signs of infection
  • muscle or joint pain
  • back pain
  • weight changes
  • rash
  • difficulty falling or staying asleep
  • difficulty with learning, memory, attention, or problem solving
  • mood changes such as anxiety, depression, confusion, or agitation
  • bone pain or difficulty moving
  • vision problems or changes in vision
  • joint pain, stiffness, redness, or swelling
  • pain in upper right part of the stomach, yellowing of skin or eyes, loss of appetite, or bleeding or bruising easily
  • shortness of breath; difficulty breathing when lying down; or swelling of the arms, legs, hands, or feet

More common

  • Abdominal or stomach pain or tenderness
  • blurred vision
  • burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings
  • change in color vision
  • clay-colored stools
  • confusion
  • dark urine
  • decreased appetite
  • defects in intelligence, short-term memory, learning ability, and attention
  • difficulty seeing at night
  • dizziness
  • fever
  • headache
  • increased sensitivity of the eyes to sunlight
  • itching or skin rash
  • joint pain, stiffness, or swelling
  • loss of appetite
  • lower back, side, or stomach pain
  • nausea and vomiting
  • problems with balance
  • sleepiness or unusual drowsiness
  • swelling of the feet or lower legs
  • trouble sleeping
  • unusual tiredness or weakness
  • yellow eyes or skin

Rare

  • Chest pain
  • decreased urine output
  • dilated neck veins
  • double vision
  • extreme fatigue
  • fainting
  • irregular breathing
  • irregular heartbeat recurrent
  • loss of memory
  • problems with memory
  • problems with speech or speaking
  • seeing double
  • seeing, hearing, or feeling things that are not there
  • swelling of the face, fingers, feet, or lower legs
  • tightness in the chest
  • trouble remembering
  • troubled breathing
  • weight gain

Drug Interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

This drug can harm a developing fetus. Verify negative pregnancy status in females of reproductive potential prior to initiating therapy. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Advise female patients of reproductive potential to use effective contraception during therapy and for at least 5 weeks after. Advise male patients with female partners of reproductive potential to use effective contraception during therapy and for 3 months after.

Lactation

Use is not recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available
The effects in the nursing infant are unknown. Because of the potential for adverse reactions in breastfed infants from this drug, advise lactating women to discontinue breastfeeding during therapy and for 7 days after.

How should this medicine be used?

Entrectinib comes as a capsule to take by mouth. It is usually taken with or without food once daily. Take entrectinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take entrectinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, or crush them.

If you vomit immediately after you take entrectinib, take another dose as soon as possible.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking entrectinib,

  • tell your doctor and pharmacist if you are allergic to entrectinib, any other medications, or any of the ingredients in entrectinib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the following: aprepitant (Emend), certain antifungal medications such as fluconazole (Diflucan), itraconazole (Omel, Sporanox), or ketoconazole; certain medications for arrhythmias such as amiodarone (Nexterone, Pacerone), procainamide, quinidine (in Nuedexta), and sotalol (Betapace, Sorine, Sotylize); azithromycin (Zithromax); clarithromycin (Biaxin, in Prevpac); diltiazem (Cardizem, Tiazac, others); erythromycin (E.E.S., Erythrocin, others); enzalutamide (Xtandi); certain HIV medications such as efavirenz (Sustiva, in Atripla), indinavir (Crixivan), nelfinavir (Viracept), nevirapine (Viramune), ritonavir (Norvir, in Kaletra, others), or saquinavir (Invirase); lithium (Lithobid); modafinil (Provigil); nefazodone; oxcarbazepine (Trileptal); phenobarbital; phenytoin (Dilantin, Phenytek); pioglitazone (Actos, in Actoplus, Duetact, Oseni); rifabutin (Mycobutin); rifampin (Rifadin, Rimactane, in Rifater); oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos); and verapamil (Calan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with entrectinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor what herbal products you are taking, especially St. John’s Wort.
  • tell your doctor if you have or have ever had a nervous system condition, a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death), a slow or irregular heartbeat, a heart attack, heart failure, or heart or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 5 weeks after your final dose. If you are a male, you and your partner should use birth control during your treatment with entrectinib and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking entrectinib, call your doctor immediately. Entrectinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking entrectinib and for 7 days after the final dose.
  • you should know that entrectinib may make cause dizziness or confusion. Do not drive a car or operate machinery until you know how this medication affects you.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
  2. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc
  3. https://pubmed.ncbi.nlm.nih.gov/32967940/
  4. https://www.cancer.gov/about-cancer/treatment/drugs/entrectinib
  5. https://go.drugbank.com/drugs/DB11986
  6. https://en.wikipedia.org/wiki/Entrectinib
  7. https://medlineplus.gov/druginfo/meds/a619049.html
  8. https://www.mayoclinic.org/drugs-supplements/entrectinib-oral-route/side-effects/drg-20470004?p=1
  9. https://www.drugs.com/mtm/entrectinib.html
  10. https://pubchem.ncbi.nlm.nih.gov/compound/Entrectinib
  11. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Entrectinib [USAN:INN]
    https://chem.nlm.nih.gov/chemidplus/sid/1108743607
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  12. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Entrectinib
    https://www.drugbank.ca/drugs/DB11986
  13. EPA DSSTox
    LICENSE
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    Entrectinib
    https://comptox.epa.gov/dashboard/DTXSID101026450
    CompTox Chemicals Dashboard Chemical Lists
    https://comptox.epa.gov/dashboard/chemical-lists/
  14. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ENTRECTINIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/L5ORF0AN1I
  15. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1983268/
    ChEMBL Protein Target Tree
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  16. Chemical Probes Portal
    Entrectinib
    https://www.chemicalprobes.org/entrectinib
  17. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    ENTRECTINIB
    https://www.dgidb.org/drugs/ENTRECTINIB
  18. Therapeutic Target Database (TTD)
    Entrectinib
    http://idrblab.net/ttd/data/drug/details/D0O0LS
  19. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  20. DailyMed
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    ENTRECTINIB
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ENTRECTINIB
  21. LiverTox
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Entrectinib
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Entrectinib/
  22. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C114984
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  23. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    Rozlytrek (EMEA/H/C/004936)
    https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek
  24. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  25. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  26. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    ATC Code
    https://www.whocc.no/atc_ddd_index/
  27. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    ENTRECTINIB
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  28. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Entrectinib
    https://www.cancer.gov/about-cancer/treatment/drugs/entrectinib
  29. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  30. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    entrectinib
    https://rxnav.nlm.nih.gov/id/rxnorm/2197862
  31. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/YMX
  32. PubChem
    https://pubchem.ncbi.nlm.nih.gov
    PFAS and Fluorinated Compounds in PubChem
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  33. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  34. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=41052806-49406333
  35. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=41052806-49406333
  36. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    Entrectinib
    https://www.wikidata.org/wiki/Q25323953
  37. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    entrectinib
    https://www.ncbi.nlm.nih.gov/mesh/2013031
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
    Protein Kinase Inhibitors
    https://www.ncbi.nlm.nih.gov/mesh/68047428
  38. KEGG
    https://www.kegg.jp/kegg/legal.html
    Therapeutic category of drugs in Japan
    http://www.genome.jp/kegg-bin/get_htext?br08301.keg
    USP drug classification
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    Anatomical Therapeutic Chemical (ATC) classification
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    Target-based classification of drugs
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    Drug Groups
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
  39. NORMAN Suspect List Exchange
    LICENSE
    Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0
    https://creativecommons.org/licenses/by/4.0/
    NORMAN Suspect List Exchange Classification
    https://www.norman-network.com/nds/SLE/
  40. PATENTSCOPE (WIPO)
    SID 392355254
    https://pubchem.ncbi.nlm.nih.gov/substance/392355254

 

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Meropenem - Uses, Dosage, Side Effects, Interactions83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Entrectinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.